

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/O699C46E51FFEN.html>

Date: July 2022

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: O699C46E51FFEN

Abstracts

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Hypersomnia, Unspecified Neurologic Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment,

Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Respiratory Depression (Hypoventilation) and Sleep Disorders.

The latest report *Orexin Receptor Type 2 - Drugs In Development, 2022*, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major

and minor projects

The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies
Involved in Therapeutics Development

Centessa Pharmaceuticals Plc

Eisai Co Ltd

Idorsia Pharmaceutical Ltd

Inexia Ltd

Johnson & Johnson

Merck & Co Inc

NLS Pharmaceuticals AG

Sumitomo Pharma Co Ltd

Synchronicity Pharma Inc

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Yangtze River Pharmaceutical Group

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles

ALKS-2680 - Drug Profile

Product Description

Mechanism Of Action

History of Events

danavorexton - Drug Profile

Product Description

Mechanism Of Action

History of Events

daridorexant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

DSP-0187 - Drug Profile

Product Description

Mechanism Of Action

History of Events

lemborexant - Drug Profile

Product Description

Mechanism Of Action

History of Events

mazindol ER - Drug Profile

Product Description

Mechanism Of Action

History of Events

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

OX2 agonist - Drug Profile

Product Description

Mechanism Of Action

History of Events

OX2 agonist (Oral) - Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

seltorexant - Drug Profile

Product Description

Mechanism Of Action

History of Events

suvorexant - Drug Profile

Product Description

Mechanism Of Action

History of Events

TAK-861 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TAK-994 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TS-142 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YNT-185 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YZJ-1139 - Drug Profile

Product Description

Mechanism Of Action

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones

Featured News & Press Releases

Jul 21, 2022: NLS pharmaceuticals announces positive opinion from European Regulators to grant Orphan Drug Designation for Mazindol ER in idiopathic hypersomnia

Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia

Jun 03, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting

Jun 02, 2022: NLS Pharmaceuticals announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of narcolepsy

May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider

May 04, 2022: NLS Pharmaceuticals achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with narcolepsy

May 03, 2022: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

May 02, 2022: Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Mar 28, 2022: NLS Pharmaceuticals announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER

Mar 16, 2022: NLS Pharmaceuticals announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy

Mar 10, 2022: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - to be presented at World Sleep 2022

Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Feb 07, 2022: NLS Pharmaceuticals to present interim top-line data for Quilience (Mazindol ER) in patients with narcolepsy at the World Sleep Congress in March 2022

Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Centessa Pharmaceuticals Plc, 2022

Pipeline by Eisai Co Ltd, 2022

Pipeline by Idorsia Pharmaceutical Ltd, 2022

Pipeline by Inexia Ltd, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by NLS Pharmaceutics AG, 2022

Pipeline by Sumitomo Pharma Co Ltd, 2022

Pipeline by Synchronicity Pharma Inc, 2022

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by Yangtze River Pharmaceutical Group, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/O699C46E51FFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O699C46E51FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970